Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) EBIT Margin: 2010-2025

Historic EBIT Margin for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -102.85%.

  • Lineage Cell Therapeutics' EBIT Margin fell 124.00% to -102.85% in Q3 2025 from the same period last year, while for Sep 2025 it was -325.27%, marking a year-over-year decrease of 6457.00%. This contributed to the annual value of -226.11% for FY2024, which is 5039.00% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its EBIT Margin stood at -102.85% for Q3 2025, which was up 85.62% from -715.37% recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' EBIT Margin peaked at -56.48% during Q4 2021, and registered a low of -1,803.07% during Q1 2021.
  • In the last 3 years, Lineage Cell Therapeutics' EBIT Margin had a median value of -304.69% in 2023 and averaged -335.10%.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' EBIT Margin spiked by 168,094bps in 2022, and later plummeted by 36,297bps in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' EBIT Margin (Quarterly) stood at -56.48% in 2021, then plummeted by 29,021bps to -346.68% in 2022, then skyrocketed by 4,199bps to -304.69% in 2023, then surged by 12,652bps to -178.17% in 2024, then tumbled by 124bps to -102.85% in 2025.
  • Its EBIT Margin stands at -102.85% for Q3 2025, versus -715.37% for Q2 2025 and -433.09% for Q1 2025.